Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE)

• Status: Recruiting
• Trial end date: 2022-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This is an open, standard therapy controlled clinical trial using a single intravenous infusion of HAM8101 (Adrecizumab) in patients hospitalized for AHF. This study will serve as a safety trial for HAM8101 (Adrecizumab) in AHF, using a dose escalating design.

Acute Heart Failure (AHF), both as deterioration of chronic stable condition or "de novo" onset constitutes a major indication of particular interest and continues to be a major health problem, with millions of people being affected, still associated with high mortality and rehospitalization rates despite numerous attempts to improve the situation.

It is believed that deteriorated vascular integrity and function, which manifests in various symptoms resulting from extravasation of fluid and solutes, is a key mechanism contributing to development and progression of the disease.

Therefore, it is warranted to start a phase 2 safety and proof of concept study with a new investigational product (IMP) that enhances the plasma concentration of bio-ADM in the circulation to restore and stabilize the vascular integrity and function in patients with AHF after initial stabilization with the current standard of care (SoC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GREAT Network Italy
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

1. Age ≥ 18 years;

2. Hospitalization due to the primary diagnosis of AHF, based on ESC 2016 Guidelines;

3. NYHA II/III/IV;

4. Must be able to be enrolled within 48h from admission to the hospital;

5. Body weight 50 - 120 kg;

6. Able and willing to provide informed written consent and written documentation of informed consent.

Exclusion Criteria:

1. NYHA Class I;

2. Dyspnea primarily due to non-cardiac causes;

3. Clinical diagnosis of acute coronary syndrome, planned PCI, life-threatening arrhythmias, planned ICD/CRT, planned cardiac surgery;

4. Recent CABG and PCI in the last 3 months;

5. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy, congenital disease, uncorrected primary valve disease needing cardiac surgery;

6. Ongoing or planned treatment with ultrafiltration or dialysis;

7. Patients that required cardiopulmonary resuscitation in the last 4 weeks prior to enrollment;

8. Systolic blood pressure at enrolment <100 mmHg or >180 mmHg;

9. Current (within 2h prior to screening) need of cardiac/respiratory mechanical support;

10. Severe pulmonary disease with chronic oxygen need at home or history of COPD >GOLD III, IPF or Bronchial Asthma;

11. Any condition or therapy, which would make the patient unsuitable for the study, or life expectancy less than 12 months (e.g. active malignancy);

12. Impaired renal function with eGFR <30 ml/min/1.73 m² calculated by Modification of Diet in Renal Disease [MDRD] formula;

13. Anemia (Hb <9 g/L or hematocrit <25%);

14. Temperature >38°C (oral or equivalent) or sepsis or active infection requiring IV antimicrobial treatment;

15. Hepatic insufficiency classified as Child-Pugh B or C;

16. Any organ transplant recipient, or patient currently listed for transplant or admitted for any transplantation;

17. Major surgery within 30 days;

18. Unwilling or unable to be fully evaluated for all follow-up assessments;

19. Participation in an interventional clinical trial involving another investigational drug or an implantable medical device within 4 weeks prior to inclusion;

20. Women of child bearing potential or women who are pregnant or breast-feeding or are not using adequate contraceptive methods [i.e. orally administered hormonal contraceptives, surgical intervention (tubal ligation), intrauterine device (IUD) and sexual abstinence];

21. Male patients with reproductive potential who refuse adequate means of contraception during and up to 3 months after end of infusion of HAM8101 (Adrecizumab).